Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.
Publication/Presentation Date
1-1-2015
Abstract
BACKGROUND: Currently there is controversy surrounding the optimal way to treat patients with prostate cancer in the post-prostatectomy setting. Adjuvant therapies carry possible benefits of improved curative results, but there is uncertainty in which patients should receive adjuvant therapy. There are concerns about giving toxicity to a whole population for the benefit of only a subset. We hypothesized that making post-prostatectomy treatment decisions using genomics-based risk prediction estimates would improve cancer and quality of life outcomes.
METHODS: We developed a state-transition model to simulate outcomes over a 10 year horizon for a cohort of post-prostatectomy patients. Outcomes included cancer progression rates at 5 and 10 years, overall survival, and quality-adjusted survival with reductions for treatment, side effects, and cancer stage. We compared outcomes using population-level versus individual-level risk of cancer progression, and for genomics-based care versus usual care treatment recommendations.
RESULTS: Cancer progression outcomes, expected life-years (LYs), and expected quality-adjusted life-years (QALYs) were significantly different when individual genomics-based cancer progression risk estimates were used in place of population-level risk estimates. Use of the genomic classifier to guide treatment decisions provided small, but statistically significant, improvements in model outcomes. We observed an additional 0.03 LYs and 0.07 QALYs, a 12% relative increase in the 5-year recurrence-free survival probability, and a 4% relative reduction in the 5-year probability of metastatic disease or death.
CONCLUSIONS: The use of genomics-based risk prediction to guide treatment decisions may improve outcomes for prostate cancer patients. This study offers a framework for individualized decision analysis, and can be extended to incorporate a wide range of personal attributes to enable delivery of patient-centered tools for informed decision-making.
Volume
10
Issue
3
First Page
0116866
Last Page
0116866
ISSN
1932-6203
Published In/Presented At
Lobo, J. M., Dicker, A. P., Buerki, C., Daviconi, E., Karnes, R. J., Jenkins, R. B., Patel, N., Den, R. B., & Showalter, T. N. (2015). Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. PloS one, 10(3), e0116866. https://doi.org/10.1371/journal.pone.0116866
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
25837660
Department(s)
Administration and Leadership
Document Type
Article